|
Abnormal behavior
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
Using diffusion tensor imaging, we examined the effect of a single nucleotide polymorphism (rs1059004) in OLIG2 previously associated with reduced gene expression, and with psychiatric disorders on fractional anisotropy in 78 healthy subjects.
|
22505278 |
2013 |
|
Abnormal behavior
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In this study, we conditionally deleted Olig2 in oligodendroglial lineage cells (Olig2 cKO) and screened the behavioral changes in adult mice.
|
31758330 |
2019 |
|
Adenomatous Polyposis Coli
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, preconditioning of BMSCs with SDF-1α reduced the protein expressions of glial fibrillary acidic protein and ionized calcium-binding adapter molecule (Iba-1) and increased the expressions of oligodendrocyte lineage transcription factor-2 (Olig-2) and adenomatous polyposis coli (APC), evaluated by immunofluorescence.
|
31631484 |
2020 |
|
Adult Giant Cell Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We conclude that GC-GBM is a distinctive subtype of glioma characterized by its vulnerability to DNA damage and that wild-type TERTp and lower OLIG2 function might induce this feature.
|
31655917 |
2020 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mean Ki-67 labeling index was 29% (range, 1.5%-80%). p53 mutation was present in 20/36 GBs (55%), whereas OLIG2 expression was positive in 29/36 GBs (80.5%).
|
31003026 |
2019 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that ARNT2 knockdown decreased the expression of SOX9, POU3F2 and OLIG2, transcription factors implicated in glioblastoma cell tumorigenicity, and repressed glioblastoma stem-like cell tumorigenic properties in vivo.
|
29149419 |
2018 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2.
|
31568682 |
2020 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We provide evidence that sorafenib has a selective action on glioblastoma stem cells, causing enrichment of cultures in differentiated cells, downregulation of the expression of stemness markers required to maintain malignancy (nestin, Olig2 and Sox2) and reducing cell clonogenic ability in vitro and tumorigenic potential in vivo.
|
23324350 |
2013 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms.
|
25384509 |
2015 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, LGR5 expression may be functionally correlated with the neurogenic competence, and be regulated by OLIG2 in GSCs.
|
23793848 |
2013 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Head of the Class: OLIG2 and Glioblastoma Phenotype.
|
27165737 |
2016 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We validated this MMS on human glioblastoma tissue sections with the use of immunohistochemistry on preclassified (YKL-40 high or mesenchymal glioblastoma and OLIG2 high or proneural glioblastoma) tumor samples (<i>n</i> = 30).
|
28744448 |
2017 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
With dual-labeling, glioblastoma had the highest percentage of OLIG2 expressing cells that were also Ki-67 positive (mean = 16.3%) whereas pilocytic astrocytoma WHO grade I and astrocytoma WHO grade II had the lowest (0.9 and 1%, respectively); most of the Ki-67 positive cells in the diffuse-type astrocytomas (WHO grade II-III) were also OLIG2 positive (92-94%).
|
21193945 |
2011 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This occurs because Omomyc interferes with proper MYC localization and itself associates with the genome, with a preference for sites occupied by MYC This is accompanied by selective repression of master transcription factors for glioblastoma stemlike cell identity such as OLIG2, POU3F2, SOX2, upregulation of effectors of tumour suppression and differentiation such as ID4, MIAT, PTEN, and modulation of the expression of microRNAs that target molecules implicated in glioblastoma growth and invasion such as EGFR and ZEB1.
|
27852622 |
2016 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate the function of OLIG2 in glial tumor cells, we have established a glioblastoma cell line, U12-1, in which the expression of OLIG2 is induced by the Tet-off system.
|
16554441 |
2006 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma.
|
26517684 |
2017 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the expression of Olig2, a protein responsible for the progression of glioblastoma was reduced by D609.
|
28802717 |
2017 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we investigated the effect of OLIG2 expression on the migration of the human glioblastoma cell line U12-1.
|
17951409 |
2007 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Induction of the miR-302/367 cluster in extensively mutated U87MG glioblastoma cells drastically suppressed the expression of transformation related proteins, for example, the reprogramming factors OCT3/4, SOX2, KLF4 and c-MYC, and the transcription factors POU3F2, SALL2 and OLIG2, required for the maintenance of glioblastoma stem-like tumor propagating cells.
|
25991553 |
2015 |
|
Adult Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
OLIG2-Expressing Progenitors May Initiate Medulloblastoma Tumor Formation.
|
31492681 |
2019 |
|
Adult Oligodendroglioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The oligodendroglioma areas showed immunoreactivity for Olig2 and mutant isocitrate dehydrogenase 1 protein, whereas the gangliocytoma and neurocytoma areas were positive for synaptophysin and NeuN.
|
24054724 |
2013 |
|
Adult Oligodendroglioma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In the current study, we found that overexpression of OLIG2 was not only found in oligodendroglioma samples and normal neural tissue but also in a wide spectrum of malignant cell lines including leukemia, non-small cell lung carcinoma, melanoma, and breast cancer cell lines.
|
16103065 |
2005 |
|
Adult Pilocytic Astrocytoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
These tumors expressed GFAP (5/6), OLIG2 (2/3), and S100 (1/1), and the pilocytic astrocytoma was negative for BRAF (V600E) mutant protein.
|
30074494 |
2018 |
|
Adult Pilocytic Astrocytoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In the current study, the pattern of OLIG2 expression in a spectrum of 90 non-oligodendroglial pediatric gliomas varied from very low levels in the ependymomas (cellular and tanycytic) to high levels in pilocytic astrocytoma, and in the diffuse-type astrocytic tumors (WHO grades II-IV).
|
21193945 |
2011 |
|
Adult Rhabdomyosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Protein expression of OLIG2, a novel marker in RMS, was investigated using antibody EP112 (Cell Marque).
|
31493794 |
2019 |